Literature DB >> 32511889

Nocturnal hypertension in primary care patients with high office blood pressure: A regional study of the MAPAGE project.

Claire Zabawa1, Clément Charra1, Anne Waldner1, Gilles Morel1, Marianne Zeller2, Adrien Guilloteau3, Katia Mazalovic1.   

Abstract

Nocturnal hypertension (NH) is an independent cardiovascular risk factor. We aimed to describe the frequency of NH among primary care hypertensive patients and to analyze NH determinants. This observational, cross-sectional, multicenter study enrolled the patients of 23 general practitioners in Burgundy region, France. We included the first patient of the day with office blood pressure ≥ 140/90 mm Hg, whatever the reason for consultation. All included patients had 24-hour ambulatory blood pressure monitoring (ABPM). Nocturnal hypertension was considered nighttime mean blood pressure ≥ 120/70 mm Hg, as per current guidelines. Medical, sociodemographic, and deprivation data were collected. Nocturnal hypertensive and non-hypertensive patients were compared. The determinants of NH were identified using logistic regression models. From July 2015 to November 2018, 447 patients were analyzed. Mean office blood pressure was 158.6/91.5 mm Hg, and 255 patients (57.0%) were taking at least one antihypertensive drug. Among the 409 (91.5%) valid ABPM, 316 (77.3%) showed NH. In multivariate analyses, male sex (odds ratio [OR] = 2.20, 95% confidence interval [CI] 1.29-3.75), first office diastolic blood pressure >100 mm Hg (OR = 5.71, 95% CI 1.53-21.40), and current smoking (OR = 5.91, 95% CI 2.11-16.56) were independent predictors of NH. Obesity was associated with a reduced risk of NH (OR = 0.43, 95% CI 0.25-0.75). No association was found between deprivation status or sociodemographic factors and NH. To conclude, NH was identified in more than three out of four patients with high office blood pressure. Male smokers with high diastolic blood pressure were most affected by NH. ABPM may improve hypertension management in these patients.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  | ambulatory blood pressure monitoring; high office blood pressure; nocturnal hypertension; primary health care

Mesh:

Substances:

Year:  2020        PMID: 32511889      PMCID: PMC8030096          DOI: 10.1111/jch.13903

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  41 in total

1.  Elevated asleep BP as predictor of type 2 diabetes and therapeutic target for prevention.

Authors:  Ramón C Hermida; Diana E Ayala; Artemio Mojón; José R Fernández
Journal:  Diabetologia       Date:  2015-12-07       Impact factor: 10.122

2.  Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk.

Authors:  Ramón C Hermida; Diana E Ayala; Artemio Mojón; José R Fernández
Journal:  J Am Coll Cardiol       Date:  2011-09-06       Impact factor: 24.094

3.  Office, home, and ambulatory blood pressures as predictors of cardiovascular risk.

Authors:  Teemu J Niiranen; Juhani Mäki; Pauli Puukka; Hannu Karanko; Antti M Jula
Journal:  Hypertension       Date:  2014-08       Impact factor: 10.190

4.  Effects of cigarette smoking on ambulatory blood pressure, heart rate, and heart rate variability in treated hypertensive patients.

Authors:  Yuko Ohta; Yuhei Kawano; Shinichiro Hayashi; Yoshio Iwashima; Fumiki Yoshihara; Satoko Nakamura
Journal:  Clin Exp Hypertens       Date:  2016-07-08       Impact factor: 1.749

5.  Nocturnal blood pressure in untreated essential hypertensives.

Authors:  Cesare Cuspidi; Carla Sala; Cristiana Valerio; Francesca Negri; Giuseppe Mancia
Journal:  Blood Press       Date:  2011-06-09       Impact factor: 2.835

6.  Nocturnal hypertension or nondipping: which is better associated with the cardiovascular risk profile?

Authors:  Alejandro de la Sierra; Manuel Gorostidi; José R Banegas; Julián Segura; Juan J de la Cruz; Luis M Ruilope
Journal:  Am J Hypertens       Date:  2013-09-23       Impact factor: 2.689

7.  Acute effects of cigarette smoking on arterial stiffness and blood pressure in male smokers with hypertension.

Authors:  Moo-Yong Rhee; Sang-Hoon Na; Young-Kwon Kim; Myoung-Mook Lee; Hae-Young Kim
Journal:  Am J Hypertens       Date:  2007-06       Impact factor: 2.689

8.  European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring.

Authors:  Gianfranco Parati; George Stergiou; Eoin O'Brien; Roland Asmar; Lawrence Beilin; Grzegorz Bilo; Denis Clement; Alejandro de la Sierra; Peter de Leeuw; Eamon Dolan; Robert Fagard; John Graves; Geoffrey A Head; Yutaka Imai; Kazuomi Kario; Empar Lurbe; Jean-Michel Mallion; Giuseppe Mancia; Thomas Mengden; Martin Myers; Gbenga Ogedegbe; Takayoshi Ohkubo; Stefano Omboni; Paolo Palatini; Josep Redon; Luis M Ruilope; Andrew Shennan; Jan A Staessen; Gert vanMontfrans; Paolo Verdecchia; Bernard Waeber; Jiguang Wang; Alberto Zanchetti; Yuqing Zhang
Journal:  J Hypertens       Date:  2014-07       Impact factor: 4.844

9.  Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality: a cross-sectional study.

Authors:  Michel Joffres; Emanuela Falaschetti; Cathleen Gillespie; Cynthia Robitaille; Fleetwood Loustalot; Neil Poulter; Finlay A McAlister; Helen Johansen; Oliver Baclic; Norm Campbell
Journal:  BMJ Open       Date:  2013-08-30       Impact factor: 2.692

Review 10.  Relative effectiveness of clinic and home blood pressure monitoring compared with ambulatory blood pressure monitoring in diagnosis of hypertension: systematic review.

Authors:  J Hodgkinson; J Mant; U Martin; B Guo; F D R Hobbs; J J Deeks; C Heneghan; N Roberts; R J McManus
Journal:  BMJ       Date:  2011-06-24
View more
  1 in total

1.  Nocturnal hypertension in primary care patients with high office blood pressure: A regional study of the MAPAGE project.

Authors:  Claire Zabawa; Clément Charra; Anne Waldner; Gilles Morel; Marianne Zeller; Adrien Guilloteau; Katia Mazalovic
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-06-08       Impact factor: 3.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.